Shanghai JMT-Bio Inc.
Shanghai JMT-Bio Inc.
Explore linked clinical trials.30 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants | Valid MeSH Conditiongs | Not yet recruiting | Phase 1 | 2026-09-25 | NCT07840729 | |
| Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-08-18 | NCT07280832 | |
| A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | Early or Locally Advanced HER2-positive Breast Cancer | Active, not recruiting | Phase 3 | 2026-07-07 | NCT06747338 | |
| A Study of JMT203 in Patients With Cancer Cachexia | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, non-small cell lung carcinoma, pancreas disorder, pancreatic neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-05-22 | NCT06868849 | |
| A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 2 | 2026-04-22 | NCT07545044 | |
| A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer | Resectable HER2-positive Breast Cancer | Recruiting | Phase 3 | 2026-04-08 | NCT07441460 | |
| SYS6090 Combination Therapy in Advanced Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-03-16 | NCT07472647 | |
| Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants | Healthy Participants | Recruiting | Phase 1 | 2026-02-19 | NCT07419698 | |
| JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan | HER2-positive Colorectal Cancer | Not yet recruiting | Phase 3 | 2026-02-03 | NCT07384377 | |
| First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors | Advanced Malignant Tumors | Recruiting | Phase 1 / Phase 2 | 2026-01-29 | NCT06877650 | |
| A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer | HER2-positive Gastric Cancer | Not yet recruiting | Phase 2 / Phase 3 | 2026-01-12 | NCT07332533 | |
| a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic disease | Recruiting | Phase 1 / Phase 2 | 2025-12-30 | NCT07140809 | |
| JMT106 Injection in the Treatment of Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm, squamous cell lung carcinoma | Recruiting | Phase 1 | 2025-12-18 | NCT07275073 | |
| The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 3 | 2025-08-21 | NCT07134205 | |
| A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy | Primary Membranous Nephropathy | Not yet recruiting | Phase 2 | 2025-06-19 | NCT07029139 | |
| JSKN003 Combined Treatment of HER2-positive Gastric Cancer | HER2-positive Gastric Cancer | Not yet recruiting | Phase 2 | 2025-05-31 | NCT06998771 | |
| Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2025-05-30 | NCT05838066 | |
| A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2025-04-08 | NCT06829459 | |
| Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Not yet recruiting | Phase 2 / Phase 3 | 2025-04-03 | NCT06908772 | |
| JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer | Disease Attributes, Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Recurrence, Stomatognathic Diseases, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Not yet recruiting | Phase 2 | 2025-03-25 | NCT06892431 | |
| JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer | Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | Recruiting | Phase 3 | 2025-03-24 | NCT06846437 | |
| A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations | Harboring EGFR Sensitive Mutations NSCLC; Locally Advanced or Metastatic Non-squamous NSCLC; Previously Untreated Systematically NSCLC | Recruiting | Phase 3 | 2024-12-16 | NCT06735391 | |
| A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2024-12-10 | NCT06725524 | |
| JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2024-04-30 | NCT06391944 | |
| JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 3 | 2024-04-23 | NCT06380348 |